Home » Stock Market Finds New Reasons To Drop, Plus A Quick Look At Acadia

stock market acadia

Stock Market Finds New Reasons To Drop, Plus A Quick Look At Acadia


Stock Market Finds New Reasons To Drop, Plus A Quick Look At Acadia

Stock’s surged in the early going before giving back the majority of the gains. I had warned in the midday commentary to use caution, which we just saw this same story play out last week. What’s the cause, not sure. Some could point to the FBI raid of President Trump’s attorney’s office Michael Cohen, or word the Federal debt is growing larger. To be truthful, I’m not sure it even matters, because every day of the week there is a new concern and worry in the marketplace, and it continues to show us how fragile the market is. Tomorrow there will be another excuse for a sell-off.

S&P 500

The making of the turnaround was in works around lunchtime, with the S&P 500 stalling out around 2,650.

spx

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Join our 901 Daily Subscribers And Get This FREE Commentary In Your E-Mail! 

Micron

Micron failed miserably at resistance around $49.75.

micron

Mott Capital Management, Michael Kramer

Mott Capital’s Reading The Markets

An In-depth Global Macro Premium Stock Market Commentary

In Video Format- See How Michael Dissects The Markets

Premium Subscription Based Membership

Just $200 Per Year – Get Your Free 2 Week Trial

Nvidia

Nvidia failed at its downtrend.

nvda

Facebook

Facebook continues to fail around $161.50

facebook

Amazon

Amazon failed again at $1440.

amazon

Advertisements

Microsoft

Microsoft failed at $93.

microsoft


JP Morgan

And last but not least, JP Morgan failed at resistance. I don’t want you to think I only write up technology stocks.

jpm

Boeing

Oh, and Boeing is close to a major breakdown.

ba


Acadia

Did you see the downgrade CNN put on Acadia, yeah CNN?

Now, first I am no Dr., I have no medical experience what so ever. So this is merely my opinion based on what I have read, studied and researched on my own. So you are welcome to agree or disagree with my opinion.

If you are an investor in Acadia, as I am, you realized reasonably quickly the database the article was referring to is FAERS data.  If you also thought you were having deja-vu when reading the article as well, you weren’t because this news, is nothing new. In fact, on Sept. 27, 2017, when the database first came out, the same thing happened! In fact, Acadia, Sarepta, and Ionis all trade lower, here is the article. Read the article.

I reread the transcript from the FDA panel meeting in March of 2016, and my impression is no different than it was over two years ago. The patient population is very sick and Nuplazid although not a perfect drug does offer hope to those suffering from hallucinations and delusion. The latest data from the ADP study showed that four individuals died on Placebo and 4 on Nuplazid, while 10 out of 91 on placebo had an SEA (10.99%), to Nuplazid 15 out of 90 (16.67%).

Take my opinion with a grain of salt, but those are my thoughts.

-Mike

Advertisements


Mott Capital’s Reading The Markets – An In-depth Global Macro Stock Market Commentary – In Video Format – See How Michael Dissects The Markets

Just $200 Per Year – Get Your Free 2 Week Trial

Recent Videos:

Trade War Worries Returns

Stock Market Rallies, Is It For Real?

Today’s Rally Looks Fragile

What Is Going On With The Stock Market! It Is Insanity!

Put On Your Rally Hats

The Bottom Is Close

Where Does The Stock Market Go From Here

Free Articles Written By Mike:

Biotech’s Exact Sciences Seen Plunging 25%

Micron Options Traders Bet Stock Will Rise 14%

Disney’s Stock Seen Rising by 17%

Qualcomm Options Traders Looking for 13% Decline

Netflix Options Traders Are Looking for a Big Rebound

Why the VIX Index Is a Bullish Sign for Stocks

Apple Stock Faces 10% Short-Term Pullback

4 Consumer Stocks That May Plunge to New Lows

Broadcom’s Battered Stock Poised for 12% Rebound

Boeing’s Stock Seen Falling Into Bear Market

IBM Traders See Stock Plunging 20%

3 Hot Biotech Stocks Facing Sharp Declines

Under Armour’s Stock Still Has Further to Fall

Intel Traders Face Big Losses As Chipmaker’s Stock Drops

Why Facebook Stock May Rebound By 25%

Amazon’s Stock May Plunge 10% Further

Tech Stocks’ Growth Engine Faces a Big Slowdown

3 Big Biotech Stocks Poised for More Declines

Why Chip Stocks May Rebound to Record Highs

Take-Two Stock Seen Rising 20% on E-Sports Demand

Square’s Soaring Stock Is Due for a Correction

Nike’s Stock Bulls May Get Burned

Why AMD Options Traders Are Bearish Long Term

Improving Earnings Will Push Stock Prices Higher

Join our 901 Daily Subscribers And Get This Commentary In Your E-Mail! Subscribe

-OR-

[vc_tweetmeme type=”follow” follow_user=”michaelmottcm” show_followers_count=”true” large_button=”true”]

Michael Kramer and Clients of Mott capital own shares of ACAD

Photo credit via Flickr

Mott Capital Management, LLC is a registered investment adviser. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Upon request, the advisor will provide a list of all recommendations made during the past twelve months. Past performance is not indicative of future.

© 2018 Mott Capital Management, LLC.  Use, publication or reproduction in any media prohibited without the permission of the copyright holder.

Tags: #stockmarket #april9 #monday #trading